Safety and tolerability

Ebixa is a well tolerated treatment. Furthermore the adverse events seen are usually mild to moderate in severity.

The following adverse events listed in the table below have been accumulated in clinical studies with memantine and since its introduction in the market:

Adverse reactions are ranked according to system organ class, using the following convention: very common (=> 1/10), common (=>1/100 to <1/10), uncommon (=>1/1,000 to =< 1/100), rare (=>1/10,000 to =< 1/1.000), very rare (=<1/10,000), not known (can not be estimated from the available data)

Alzheimer’s disease has been associated with depression, suicidal ideation and suicide. In postmarketing experience these events have been reported in patients treated with Ebixa.